Get ready for groundbreaking innovation in healthcare solutions.
We develop an innovative therapy to address chronic liver diseases, including Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and steatohepatitis (MASH)
Advanced Therapies: Peptidomimetic treatment designed to target key mechanisms involved in liver inflammation, fibrosis, and metabolic dysfunction
Mechanism-Based Research: Leveraging SOCS1-derived peptides for safer, more effective therapeutic solutions.
Patient-Centered Development: Harmonizing metabolic pathways in liver disease to improve quality of life for patients with diabetes and obesity.
announcement
New therapeutic peptides slow progression of fatty liver disease of metabolic origin.
A new family of therapeutic peptides has demonstrated protective effects against metabolic dysfunction-associated fatty liver disease (MASLD)
CIBER research group
more info: c.gomez@uam.es
Parque Científico de Madrid. Campus de Cantoblanco. C/ Faraday, 7. 28049 Madrid
© 2025 LIFESOMIX All rights reserved.
